On May 24, 2024, the CGCS 2024 (5th) international cell and gene therapy Chinese summit ended successfully in Nanjing. This time, it was initiated by the CGCS Organizing Committee, and the experts of the United CGCS Organizing Committee and the online selection were grandly released: CGCS Awards Qiming Star Award.

     Shandong Xinbo Drug Research Co., Ltd. has won unanimous recognition in the industry with excellent technical services and excellence, and has won the "CRO Cooperation Star in the CGT field in 2024" awards.

The CGCS Awards Awards Award Evaluation Campaign was initiated by the CGCS Organizing Committee, and the CGCS Organizing Committee experts and online selection were released. [Qi Xing] is a particularly bright "morning star" appearing on the horizon of the east when dawn, symbolizing a new day is coming. Every industry has such a group of "morning stars" enterprises. At a difficult time in the industry, it brings everyone hope and guides the industry's forward direction.

Since its establishment in 2010, Shandong Xinbo Pharmaceutical Research Co., Ltd. has provided more than 10,000 services to more than 540 pharmaceutical companies, new drug research and development institutions and scientific research institutes at home and abroad. In accordance with the requirements of domestic and foreign regulations, more than 400 clinical pre -clinical evaluation services have been completed, including small molecular drugs, biomarbon drugs, new types of prevention and therapeutic vaccines, Chinese medicine/natural drug evaluation work, helping R & D units obtain clinical approval of new drugs. Yu Zhi, especially in recent years, has also accumulated rich experience in the evaluation of the rapid development of therapeutic vaccines, cells and gene therapy drugs.
In preclinical evaluation of cells and gene therapy, MRNA & small nucleic acid innovative drugs, a mature technology platform is established, a specific molecular detection method is established, and targeted effectiveness and safety evaluation is performed. Among them, the two test objects rated by Shandong Xinbo Drugs in 2023 are MRNA vaccines (acceptance number: CXSL2300483), and the first INKT cell product GKL-006 injection solution for liver cancer (accept number: CXSL230056777 ) Receive clinical approval.
     Looking forward to the future, Shandong Xinbo Pharmaceutical Research Co., Ltd. will continue to adhere to the core concept of "excellence", help the global biomedical and medical and health industries sustainable, and benefit more patients.

The CGCS Awards Rising Star Award is initiated by the CGCS Organizing Committee and jointly announced by CGCS organizing committee experts and online selection. The Morning Star "is a particularly bright" morning star "that appears on the eastern horizon at dawn, symbolizing the arrival of a new day. Every industry has a group of "Morning Star" enterprises that bring hope and guide the industry's direction during difficult times.

Since its establishment in 2010, Shandong Xinbo Pharmaceutical Research Co., Ltd. has provided over 10000 services to more than 540 pharmaceutical companies, new drug research institutions, and research institutes both domestically and internationally. We have completed preclinical evaluation services for nearly 400 innovative drugs in accordance with domestic and foreign regulatory requirements, including small molecule drugs, biomacromolecule drugs, new preventive and therapeutic vaccines, and traditional Chinese medicine/natural medicine evaluation work. We have helped research and development units obtain more than 100 clinical approvals for new drugs, especially in the evaluation of rapidly developing therapeutic vaccines, cell and gene therapy drugs in recent years, and have accumulated rich experience.
We have established a mature technology platform for preclinical evaluation of innovative drugs in cell and gene therapy, mRNA&small nucleic acid, and developed specific molecular detection methods for targeted efficacy and safety evaluation. Among them, two test substances evaluated by Shandong Xinbo Pharmaceutical Research Co., Ltd. in 2023, namely mRNA vaccine (acceptance number: CXSL2300483) and GKL-006 injection, the first iNKT cell product for liver cancer in China (acceptance number: CXSL2300567), have obtained clinical approval.
Looking ahead to the future, Shandong Xinbo Pharmaceutical Research Co., Ltd. will continue to adhere to the core concept of "striving for excellence", assist in the sustainable development of the global biopharmaceutical and healthcare industries, and benefit more patients.